Dupilumab, a simple pre-filled pen that people inject themselves with every two weeks, is the first biologic that targets both the symptoms of COPD and an underlying cause of the disease. It brings ...
NICE has approved the first targeted treatment for chronic obstructive pulmonary disease (COPD), offering a new option to up ...
NICE has estimated that around 40% of people with COPD have elevated blood levels of eosinophils and, if half the eligible ...
Nearly 30,000 people in England living with chronic obstructive pulmonary disease could see their lives transformed after the ...
A biologic injection that reduces chronic obstructive pulmonary disease (COPD) flare-ups by around a third has been approved for use on the NHS in England and Wales. The National Institute for Health ...
NICE has recommended dupilumab for adults with uncontrolled COPD and raised eosinophils, citing fewer exacerbations and ...
The National Institute for Health and Care Excellence (NICE), has published final draft guidance recommending dupilumab as a ...
AJMC®: What recent developments in the therapeutic landscape of chronic obstructive pulmonary disease (COPD) do you think have the greatest potential to shift how treatment is managed? Dr Martinez: ...
Temple Health is testing a tiny, flexible scaffold aimed at relieving a common problem for emphysema patients: overinflation of the lungs due to trapped air.
Join Rich Jones and Dr Mitchell Rothstein as they talk advances in COPD treatment. FREE lunch from Carrabba’s Italian Grill is included. Is chronic coughing or shortness of breath holding you back?
Some results have been hidden because they may be inaccessible to you
Show inaccessible results